Login / Signup

Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application.

Andrew Embleton-ThirskElizabeth DeaneStephen TownsendLaura FarrellyBabasola PopoolaJudith ParkerGordon RustinMatthew Robert SydesMahesh ParmarJonathan LedermannRichard Kaplan
Published in: Clinical trials (London, England) (2019)
The conduct of this pragmatic, academic-sponsored trial was sufficient given the robustness of the results, shown by the results remaining largely unchanged following retrospective verification despite not being designed for use in a marketing authorization. The burden of such comprehensive retrospective effort required to ensure the results of ICON6 were acceptable to regulators is difficult to justify.
Keyphrases
  • study protocol
  • cross sectional
  • phase iii
  • clinical trial
  • phase ii
  • randomized controlled trial
  • transcription factor
  • open label
  • risk factors
  • deep learning
  • medical students